Drug Profile
ET 601
Alternative Names: ET601Latest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Eureka Therapeutics
- Developer Eureka Therapeutics; Five Prime Therapeutics
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 28 Mar 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 01 Feb 2016 Preclinical trials in Solid tumours in USA (unspecified route) prior to February 2016 (Eureka Therapeutics pipeline, February 2016)